Business Wire

MA-TAKEDA

Share
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

Takeda (TSE:4502/NYSE:TAK ) and the New York Academy of Sciences today announced the winners of the fourth Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in gastroenterology. Each winner receives an unrestricted prize of $200,000 USD.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005028/en/

The 2022 Senior Scientist Award winner is Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology and Dr. Robert J. Glaser Distinguished University Professor at Washington University School of Medicine in St. Louis. Dr. Gordon is widely recognized as the “Father of Microbiome Science” and has served as the research mentor for more than 140 doctoral students and post-doctoral fellows who have become the next generation of leaders in the field. His pioneering interdisciplinary research has revealed the profound effects of the human gut microbial community on physiology and metabolism. Dr. Gordon’s preclinical studies have yielded fundamental insights about the mechanisms that underlie the formation and functioning of the human gut microbiome, as well as its causal links to disease states, including malnutrition. Dr. Gordon’s group has developed microbiome-targeted therapeutic foods for the precision repair of the gut microbiomes of malnourished children and restoration of their growth.

“This award is a wonderful recognition of the excitement and promise that the field of microbiome research offers, and of the collective efforts of the inspiring group of talented students, staff, and collaborators who I've been privileged to work with as we strive to better understand how the gut impacts our health,” said Dr. Gordon.

The 2022 Early-Career Scientist Award winner is Elaine Y. Hsiao, Ph.D., De Logi Associate Professor of Biological Sciences at UCLA. Dr. Hsiao has made groundbreaking discoveries into how the gut microbiome influences the brain and behavior. Her research has upended conventional thinking about the cause and treatment of neurological diseases such as autism and epilepsy. Some of Dr. Hsiao’s most impactful work investigating the influence of the maternal microbiome on fetal brain development has laid the foundation for hypotheses of microbial contributions to risk for neurodevelopmental disease. Dr. Hsiao has also advanced the understanding of how microbiota influence serotonin-producing endocrine cells in the gut — research that has the potential to affect the understanding of intestinal and neurological diseases.

“Winning the Innovators in Science Award is a great privilege for me as an early-career scientist,” said Dr. Hsiao. “Not only does it signal a welcome to new researchers to help advance the field, it also recognizes the discoveries made possible by my talented and inspiring colleagues in the lab who share my dedication to uncovering interactions between the gut, its native microbes, and the brain. This award will continue to motivate me to go where science leads, and toward better understanding how life works in ways that I hope will one day benefit people.”

“The work of Dr. Gordon and Dr. Hsiao to uncover more about the role of our gut microbiome in disease pathology and apply that understanding to create meaningful interventions for patients suffering from gastrointestinal, neurological diseases, and beyond is truly inspiring,” said Andrew Plump, M.D., Ph.D., president, Research & Development at Takeda. “We proudly support the Innovators in Science Award because at Takeda we deeply value the pursuit of science and those who push the boundaries of what is possible to dramatically improve people’s lives.”

“We are pleased to join Takeda in championing the tireless work of researchers around the world,” said Nicholas Dirks, Ph.D., president and CEO of the New York Academy of Sciences. “The 2022 Innovators in Science Award winners are pursuing groundbreaking medical research that reveals the workings of the gut microbiome to potentially bring innovations to patients everywhere who are affected by gastrointestinal disease and more.”

The 2022 winners will be honored at the Innovators in Science Award ceremony and symposium October 13-14, 2022, in Boston. For more information and to register for the 2022 Innovators in Science Award virtual symposium, please visit: https://www.nyas.org/awards/innovators-in-science-award/

About the Innovators in Science Award

The Innovators in Science Award grants two unrestricted prizes of US $200,000 each year: one to an early-career scientist and the other to a well-established senior scientist who have distinguished themselves for the creative thinking and impact of their research. The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government, or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising early-career scientists and their most outstanding senior scientists. The therapeutic focus rotates each year through one of five fields — neuroscience, gastroenterology, rare diseases, oncology, and regenerative medicine. The 2022 focus was gastroenterology, next year the focus will be on oncology. Prize winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines. The New York Academy of Sciences administers the Award in partnership with Takeda.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com .

About the New York Academy of Sciences

The New York of Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at www.nyas.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press release

At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra

PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press release

PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s

FIFA World Cup™ Trophy Tour by Coca-Cola to Begin Global Journey Ahead of FIFA World Cup 2026™16.12.2025 14:00:00 CET | Press release

Coca-Cola and FIFA celebrate 20 years of FIFA World Cup™ Trophy Tour by Coca-Cola The Coca-Cola Company and FIFA are kicking off the sixth FIFA World Cup™ Trophy Tour by Coca-Cola, giving thousands of fans across the globe the opportunity to see the original FIFA World Cup™ Trophy ahead of FIFA World Cup 2026™. FIFA World Cup 2026 is set to be the biggest yet—spanning three host nations, Canada, Mexico and the United States, with more teams, more matches and more celebrations than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216393608/en/ FIFA World Cup™ Trophy Tour by Coca-Cola As a long-standing partner of FIFA, Coca-Cola has the exclusive rights to the FIFA World Cup Trophy Tour by Coca-Cola. Beginning Jan. 3, 2026, in Riyadh, Saudi Arabia, the original FIFA World Cup Trophy will visit 30 FIFA Member Associations across 75 stops and more than 150 tour days, giving fans around the world a once-in-a-lifeti

1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release

1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi

Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release

Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye